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Abstract 
Background: Many prognostic factors have been identified in 
chronic lymphocytic leukemia (CLL) but new ones are still desired. The 
biological characterization of CLL is now being translated into novel 
treatment strategies. One new prognostic factor, and therapeutic target, may 
be BFL1. It is both a serum and a molecular marker that contributes to the 
progression of CLL and its resistance to chemotherapy.  The aim of this 
study was to evaluate the prognostic value of BFL1 and to assess its 
correlation with other known prognostic markers in CLL for the cladribine 
and cyclophosphamide regimen (CC). Methods: qPCR TaqMan® Low 
Density Array was used for gene expression measurements. Assessment of 
CD38, ZAP70 and BFL-1 proteins expression was done by means of flow 
cytometry. Serum TK activity was measured by immunoassay. Results: 
Protein BFL1 expression was found to be significantly higher in CLL 
patients than healthy volunteers (p=0.001). Moreover its level was 
significantly higher in patients with no response (NR) to CC therapy 
(p=0.009). The expression of BFL1 was considerably down regulated during 
CC treatment and BFL1 mRNA levels were inversely correlated with 
apoptotic response. In addition, protein BFL1 expression was found to be 
similar to thymidine kinase (TK) concentration regarding treatment response. 
As far as other markers are concerned, a positive correlation was identified 
between BFL1 and TK (r=0.52, p=0.01). Conclusions: Our findings suggest 
that BFL1 contributes to chemoresistance and may be a co-existing 
prognostic factor in CLL in the future.  
 
Keywords: Chronic Lymphocytic Leukemia, BFL1, thymidine kinase, 
microarray gene expression, cladribine 
 
Introduction 
 Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia 
in the western world. The disease affects mostly elderly CLL patients (81% 
of patients are over 60), but recently it has been observed more frequently in 
younger people. Recent advances in understanding the biology of CLL have 
resulted in the development of novel agents targeting key prosurvival 
pathways in the neoplastic B cell. 
 Among prognostic factors in CLL, the most important are clinical 
stage of the disease, markers of tumour load, such as thymidine kinase (TK), 
cellular protein expression (e.g., CD38 and ZAP70), as well as genetic 
parameters including immunoglobulin heavy chain variable gene segment 
(IGHV) mutational status, genomic aberrations and individual gene 
mutations (Oscier, et al., 2002) (Zenz, et al., 2010).  
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 Among serum markers, TK deserves special attention. TK takes part 
in DNA synthesis and catalyses the phosphorylation of thymidine to 
thymidinomonophosphate (Wintersberger, 1997). It has been already 
indicated that the activity of TK is a reliable marker of tumor cell 
proliferation (Ke & Chang, 2004), mostly a cytoplasmic (TK1) isoenzym 
(Wintersberger, 1997), (Ke & Chang, 2004), (Pflug, et al., 2014). The other 
serum factor, which correlates with prognosis, is basic fibroblast growth 
factor (bFGF). It exists in basement membranes as well as in the 
subendothelial extracellular matrix in normal blood vessels. As long as no 
signal peptide is present, bFGF remains bound to the membrane. However, 
during tumor development, the action of heparan sulphate-degrading 
enzymes activates bFGF and thus triggers an angiogenesis, which enhances 
the proliferation of epithelial cells and fibroblasts involved in the regulation 
of cellular replication (Kühn, et al., 2012), (Bertolini, Mancuso, Shaked, & 
Kerbel, 2007). 
 Although many prognostic factors in CLL have been already 
identified, new ones are still being revealed. One such factor might be the 
activity of BFL1, which could be either a serum marker or a molecular 
marker, which contributes to disease progression and resistance to 
chemotherapy (Morales, et al., 2005), (Olsson, et al., 2007). BFL1 is an 
antiapoptotic member of the BCL2 family. The protein encoded by this gene 
has been previously reported as a regulatory marker of the other members of 
BCL2 family proteins. Working in antagonism, the antiapoptotic proteins 
BCL2, BCL-XL, MCL1 or BFL1 (also called BCL2A1 or A1) inhibit BAX 
and BAK activation and apoptosis (Danial, & Korsmeyer, 2004). Of the 
antiapoptotic proteins, BFL1 has the highest affinity to BID (Kim, et al., 
2006), (Chen, et al., 2005). BFL1 has been reported as a direct 
transcriptional target of NF-κB (Chen, Edelstein, & Gelinas, 2000). In 
lymphocytes B, BFL1 is induced by CD40 ligation and has been shown to 
protect from apoptosis triggered by ligation of the B-cell receptor or FAS 
(Craxton, Chuang, Shu, Harlan, & Clark, 2000). Higher BFL1 expression has 
been found in several types of cancer, for example diffuse large B-cell 
lymphoma (DLBCL), acute myeloid leukemia (AML), lymphoma and 
melanoma (Shipp, et al., 2002), (Piva, et al., 2006), (Haqq, et al., 2005). 
Moreover, it is thought to be required for tumor initiation, maintenance and 
chemoresistance. The BFL1 gene has been found to be overexpressed in B-
CLL cells with an apoptosis-resistant phenotype (Morales, et al., 2005), 
(Olsson, et al., 2007), (Aguilar-Santelises, Rottenberg, Lewin, Mellstedt, & 
Jondal, 1996) (Kitada, et al., 1998).  
 Several chemotherapies have been used for the treatment of CLL, 
such as alkylating agents, antracyclines, corticosteroids, purine nucleoside 
analogues (PNAs) and monoclonal antibodies. Purine analogues (cladribine, 
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fludarabine and pentostatin) were introduced in the 1980s. Among the class 
of PNAs an important role is played by fludarabine (FA) and cladribine (2-
CdA), which currently are the most frequently used in CLL therapy, in our 
hematology clinic cladribine has been used since 1995. The chemical 
structure of both drugs is similar to adenosine. They require phosphorylation 
to activate metabolites, and the induction of apoptosis, as well as 
cytotoxicity, depends on their accumulation of their triphosphate form (PNA-
TP). The mechanism of action of both drugs is similar, however minor 
differences are observed. Gene expression profiling (GEP) under the 
influence of both drugs is also similar, which proof the similar mechanism of 
action (Franiak-Pietryga, et al., 2012a). 
 Although, antibody anti-CD20 is standard today in CLL treatment, 
we have already checked the GEP under the influence on RCC (Franiak-
Pietryga, et al., 2012b). In this paper we would like to evaluate only CC 
regimen and compare to previous study.  
 The aim of this study was to evaluate the value of BFL1 and to assess 
the correlation between BFL1 and other known markers in CLL for the 
cladribine and cyclophosphamide regimen.  
 
Materials and Methods 
Patients 
 Peripheral blood samples from 24 previously untreated progressive 
CLL patients (Rai 3 and 4) were obtained after informed consent was given. 
The diagnosis of CLL was based on IWCLL standard criteria (Hallek, et al., 
2008). The Ethics Committee of the Medical University of Lodz, Poland 
(RNN/196/07/KE) approved the study. The characteristics of the patients are 
given in Table 1. Ten healthy volunteers were enrolled into the study as a 
negative control. 
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Table 1. Characteristics of the CLL patients 
Patient No. Age/ 
Gender 
Months since 
diagnosis 
Blood 
lymphocyte 
count (x109l-1) 
IGHV 
mutation 
 
CD38 Cytogenetic 
abnormalities 
Treatment 
response 
CLL 1 74/M 0 503 n.d. - del(13)(q14), del(11)(q22) CR 
CLL 2 53/M 12 120 unmutated + del(13)(q14), del(11)(q22) CR 
CLL 3 69/M 0 216 mutated - del(13)(q14) CR 
CLL 4 70/M 0 163 unmutated - del(11)(q22) NR, † 
CLL 5 65/M 15 75 unmutated - del(13)(q14), del(11)(q22) NR 
CLL 6* 53/M 38 130 unmutated - del(13)(q14) PR 
CLL 7 53/M 14 84 unmutated - del(13)(q14), del(17)(p13) NR, † 
CLL 8 70/F 156 86 n.d. - del(13)(q14) CR 
CLL 9 66/M 28 157 n.d. + del(13)(q14), del(11)(q22) PR 
CLL 10 63/M 0 34 mutated - del(13)(q14), del(17)(p13) CR 
CLL 11 41/F 3 75 n.d. - del(13)(q14) CR 
CLL 12 75/F 6 115 n.d. - n.d. PR 
CLL 13* 76/F 43 120 unmutated + del(13)(q14), del(11)(q22) NR, † 
CLL 14 51/M 0 109 unmutated - del(11)(q22), trisomy 12 CR 
CLL 15 74/M 28 97 unmutated + del(13)(q14), del(17)(p13) CR 
CLL 16 68/M 32 159 n.d. - del(13)(q14) CR 
CLL 17* 72/M 69 106 unmutated - del(13)(q14) CR 
CLL 18* 75/F 36 290 unmutated + del(13)(q14), del(11)(q22) CR 
CLL 19* 60/M 1 52 unmutated - del(13)(q14) CR 
CLL 20* 66/M 0 634 unmutated - del(13)(q14) NR 
CLL 21* 63/F 1 55 unmutated + n.d. NR, † 
CLL 22* 77/M 5 24 unmutated + del(13)(q14), del(11)(q22) NR, † 
CLL 23 70/M 2 30 n.d. + del(13)(q14), trisomy 12 CR 
CLL 24 58/M 0 315 n.d. + n.d. NR, † 
M, male; F, female; IGHV, immunoglobulin heavy chain variable gene; 
NR, no response; CR, complete remission; PR, partial remission; †, death 
n.d., not determined; *, patients selected to microarray analysis 
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CLL therapy 
 All the patients received cladribine and cyclophosphamide (CC) 
treatment by i.v. infusion according to the following schedule: cladribine 
0.12mg/kg – days 1-3, cyclophosphamide 600mg/m2 – days 1-3. The 
regimen was repeated every 4 weeks for 6 courses. 
 
Isolation of mononuclear cells and serum collection 
 Blood samples were collected from all patients before and 2 weeks 
after the first CC cycle. Peripheral blood mononuclear cells (PBMNCs) were 
separated from EDTA blood as previously described (Franiak-Pietryga, et 
al., 2012b). Mean B-cell (CD19+) purity was >95% as measured by flow 
cytometry (FACS). The serum obtained from blood was stored at -80°C until 
assayed for TK and bFGF. 
 
PCR amplification of IGHV-D-J rearrangements; immunoglobulin 
sequence analysis and cytogenetics 
 IGHV mutational status and cytogenetic abnormalities were assessed 
according to previously published methods (Franiak-Pietryga, et al., 2012b). 
IGHV rearrangements were performed on genomic DNA (gDNA) extracted 
from peripheral blood. Monoclonal PCR products were purified on low-
melting-point agarose gel and than subjected to sequencing on an ABI 
sequencer. The sequence data was analysed using the international 
ImMunoGeneTics information system (IMGT®) database and tools. 
Sequences with a germline identity of 98% or higher were considered 
unmutated, and those with an identity less than 98% were considered 
mutated.  
 Cytogenetic aberrations were evaluated using interphase fluorescence 
in situ hybridization (FISH) with the standard panel of probes (Abbott 
Molecular, USA)  (Franiak-Pietryga, et al., 2012b).  
 
mRNA quantification by real-time reverse transcription polymerase 
chain reaction 
 Total RNA was extracted with the use of the RiboPure Blood Kit 
(Ambion, USA) according to the manufacturer’s instructions. Total RNA 
(0.5μg) was reversed transcribed to complementary DNA (cDNA) using 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
USA). The BFL1 mRNA levels were determined in a Rotor-Gene®Q using a 
predesigned Assay probe (Hs00187845_m1 probe, Applied Biosystems). 
The relative expression of each gene was quantified by the comparative 
cycle threshold method (ΔΔCt), using β-actin (Hs99999903_m1 probe, 
Applied Biosystems) as an endogenous control, and untreated samples as a 
calibrator. 
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cDNA expression microarray 
 The 384 TaqMan® Low Density Array Human Apoptosis Panel 
(Applied Biosystems, USA) containing primers without cDNA and other 
necessary reagents for PCR analysis of 96 gene transcripts (93 examined, 3 
controls) was used as described previously (Franiak-Pietryga, et al., 2012b). 
Prepared cDNA samples from 0.5 g of RNA were subjected to real-time 
PCR in duplicate in the TaqMan® 7900HT Sequence Detection System 
(Applied Biosystems).  
 The complete list of microarray data is available at Gene Expression 
Omnibus (accession no. GSE55686). 
 
Gene expression profile analysis 
 The relative expression of each gene was quantified by the 
comparative cycle threshold method (  Ct, ddCt), using 18S as an 
endogenous control (a housekeeping gene) (Franiak-Pietryga, et al., 2012b).   
 The difference in expression of a certain gene was considered 
significant only if the fold change values (RQ), defined as the differential 
gene expression before and after treatment, were >1.0. The purpose of data 
analysis was to identify genes with the most differential expression under CC 
treatment. 
 The dendrogram and matrix showing the hierarchical clustering of 80 
genes are based on gene expression data generated from 7 CLL samples (Fig. 
1). The hierarchical clustering algorithm was evaluated in accordance with 
the average-linkage clustering method (Hartigan, et al., 1975), (Eisen, 
Spellman, Brown, & Botstein, 1998). The rows represent individual genes, 
and the columns represent individual mRNA samples. The relative level of 
gene expression is depicted according to the colour scale for the matrix. 
Microarray analysis was used as a screening. 
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Fig. 1. Heatmap of relative gene expression levels (log ratio of expression after treatment to 
expression before treatment, log RQ). 
log (RQ)    
 
 
 
Assessment of CD38, ZAP70 and BFL-1 expression 
 CD38 and ZAP70 expression were measured immediately prior to the 
start of the CC regimen using the FACS method. BFL1 expression was 
assessed before and 2 weeks after the first CC cycle. PBMNCs at a 
concentration of 1x106 were incubated with anti-CD38-FITC or anti-ZAP70-
FITC or anti-BFL1-FITC. Samples were analysed in a Becton Dickinson 
FACSCanto ™ II system equipped with an argon laser (λ=488 nm), using 
1x104 cells for each determination. The cut-off values for CD38 and ZAP70 
were 30% and 20%, respectively. In BFL-1 case mean fluorescence intensity 
(MFI) level was calculated. 
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Serum TK activity 
 The s-TK assay was performed with a commercially available 
quantitative immunological assay (Biomedica, Poland). This is a non-
radioactive assay. In this technique 3'-azido-2',3'-deoxythymidine (AZT) is 
first phosphorylated to AZT 5'-monophosphate (AZTMP) in the sample by 
TK1. AZTMP is measured by immunoassay with anti-AZTMP antibodies 
and AZTMP-labeled peroxidase. The assay runs in a closed system using 
laboratory equipment from DiaSorin LIAISON® (USA). The TK1 activity is 
expressed in units per liter, with 7 U/l as the upper level in healthy subjects.  
 
Serum bFGF concentration 
 Serum bFGF concentrations were measured using a commercially 
available enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, 
R&D Systems Inc., USA). The assay employs quantitative sandwich enzyme 
immunoassay technique. Standards and samples were assayed as duplicates. 
Serum before measurements was stored at -70°C. Assay sensitivity was less 
than 3.0 pg/ml. The procedure is described in detail at 
www.rndsystems.com/pdf/dfb50.pdf. 
 
Response criteria 
 Treatment efficacy was assessed according to IWCLL guidelines at 
least 2 months after completion of the therapy (Hallek, et al., 2008). A 
complete response (CR) required the absence of symptoms and 
organomegaly, a normal blood cell count (leukocytes count 1.5 x 109/L 
(1500/μL) or more), untransfused hemoglobin concentration > 11.0 g/dL and 
platelet count > 100 x 109/L (100 000/ μL), lymph nodes should not be larger 
than 1.5 cm in diameter. Partial response (PR) was defined as a decrease in 
the number of blood lymphocytes by ≥ 50% from the value before therapy 
and/or a decrease in lymphadenopathy, splenomegaly and hepatomegaly by 
≥ 50% from the value before therapy. Hematologic toxicity was evaluated 
according to the criteria of IWCLL guidelines (Hallek, et al., 2008).      
 
Statistical analysis 
 Comparisons of values were made with the Wilcoxon rank test and 
Χ2 test using STATISTICA v. 8.0. Results were considered statistically 
significant when P < 0.05. Correlations were assessed by the Spearman rank 
test. 
 
Results 
Characteristics of CLL patients 
 All 24 patients enrolled into the study were treated with a CC 
regimen as the first line therapy. Thirteen patients achieved CR, 3 patients 
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PR and 8 patients did not respond (NR) to therapy. In the NR group, 6 
patients died. One patient died because of infection, while the other 5 due to 
progression of CLL. 
 In 16 out of 24 patients IGHV mutation status was assessed. Two 
patients were IGHV-mutated, while 14 were IGHV-unmutated. IGHV-
mutated patients attained CR. Among IGHV-unmutated patients, the 
following treatment response was observed: 6 patients CR, 1 patient PR, and 
7 patients NR.  CD38 was assessed in the whole group of patients. Nine out 
of 24 patients were CD38(+). In this group, 4 patients achieved CR, 1 patient 
PR and 4 patients NR. In the group of patients with CD38(-) the following 
treatment response was observed: 9 patients CR, 2 patients PR and 4 patients 
NR (Table 1). Among cytogenetic abnormalities, that were assessed in 21 
patients, del(17) was evaluated in 3 patients, 19 patients had del(13) and 8 
patients had del(11). The characteristics of the group of patients selected for 
microarray analysis is shown in Table 2. All patients in microarray group 
were IGHV-unmutated. 
 Table 2. Characteristics of the CLL patients selected for microarray analysis. 
        Patients 
Nr                    Sex    
Age     
IGHV  
mutation a 
   ZAP70 a 
% cells  status 
      CD38 b 
% cells status 
   Cytogenetic 
abnormalities c 
cc2  (CLL 19)      M     
60       
unmutated 
0.28         
1.36         del(13q) 
cc3  (CLL 21)      F      
63        
unmutated 0.23         32.09      + n.d. 
cc4  (CLL 6)        M     
53        
unmutated 3.83         4.72         del(13q) 
cc5  (CLL 22)      M     
77        
unmutated 6.91         74.45      + del(13q),del(11
q) 
cc6  (CLL 17)      M     
72        
unmutated 7.94         1.76         del(13q) 
cc7  (CLL 13)      F      
76         
unmutated 13.85       26.86      + del(13q), 
del(11q) 
cc8  (CLL 20)      M     
66        
unmutated 19.48       4.74         del(13q) 
CC, cladribine cyclophosphamide; ZAP70, zeta-associated protein 70; IGHV, 
immunoglobulin heavy chain variable gene. 
a,b The values demonstrate the percentage of cells defined as ZAP70 or CD38 positive. 
c Cytogenetic variations were measured by means of FISH method 
 
Serum markers in the response to treatment 
Thymidine kinase (TK) and Basic fibroblast growth factor (bFGF) 
 The serum TK and bFGF levels were significantly higher in CLL 
patients as compared with those of healthy volunteers (p=0.001) (Table 3).  
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Table 3. The median values of BFL1 expression, bFGF and TK serum concentrations in 
CLL patients before and after 2 weeks of the first CC cycle and in controls. 
Parameter 
Healthy donors 
Median 
(Range) 
Before treatment 
Median 
(Range) 
After treatment 
Median 
(Range) 
Statistical 
comparison (p) 
 (3) (1) (2) (4) 
BFL1 (MFI) 
248.48 
(179.25-320.3) 
n = 20 
746.41 
(242.13-1885.57) 
n = 22 
667.77 
(333.18-1678.87) 
n = 22 
1 vs. 2 = 0.03 
1 vs. 3 = 0.001 
bFGF (pg/ml) 
9.4 
(0-20) 
n = 20 
43.94 
(0-348.65) 
n = 19 
6.27 
(0-93.35) 
n = 19 
1 vs. 2 = 0.0009 
1 vs. 3 = 0.001 
TK (U/l) 
7.75 
(1.1-15.1) 
n = 20 
30.45 
(6.5-100) 
n = 24 
26.40 
(6.4-100) 
n = 24 
1 vs. 2 = 0.03 
1 vs. 3 = 0.001 
n – number of patients;  MFI – Mean Fluorescence Intensity 
TK – thymidine kinase   bFGF – basic fibroblast growth factor 
 
Table 3a. Values of BFL1 expression, bFGF and TK serum concentrations for particular 
single CLL patient. 
BCL2-A1 (BFL-1) Thymidine kinase (TK) 
FGF 
(pg/ml) 
Patient 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
CLL1 628.81 493.05 13.8 17.2 31.6 6.93 
CLL2 640.11 661.29 NA NA NA NA 
CLL3 645.06 800.25 24.7 26.3 0 0 
CLL4 824.01 724.7 49.8 42.7 NA NA 
CLL5 927.75 883.2 84.1 100 6.93 5.6 
CLL6 976.43 768.27 35 30.5 90.93 2.93 
CLL7 727.77 873.56 NA 87.5 NA NA 
CLL8 1750.47 1040.98 14.9 19.5 226.93 2.27 
CLL9 665.13 560.48 19.2 8 27.18 0 
CLL10 809.84 674.24 47.2 60.9 NA NA 
CLL11 543.95 754.09 18.8 10.5 248.27 14.93 
CLL12 631.11 387.32 35.9 12.9 76.6 18.93 
CLL13 1013.98 595.65 97.6 6.4 42.47 4.93 
CLL14 938.84 365.62 55.1 32.7 NA NA 
CLL15 943.34 1678.87 80.1 80.5 NA NA 
CLL16 242.13 333.18 18.3 12.6 NA 2.93 
CLL17 630.26 1231.09 7.9 13.9 53.65 45.12 
CLL18 660.77 480.91 15.2 20.5 751 93.35 
CLL19 1521.41 381.56 100 100 34.82 17.47 
CLL20 1885.57 558.17 6.5 100 51.88 30.71 
CLL21 977.47 353.36 100 100 43.94 53.94 
CLL22 268.53 737.88 25.9 26.5 38.06 29.24 
CLL23 765.05 NA 16.7 12.7 0 0 
CLL24 NA NA 88.02 100 0 0 
CLL25 NA NA 30.45 28.6 NA NA 
CLL26 725.99 NA 72.6 21.1 348.65 29.24 
CLL27 NA NA 12.4 19.3 219.82 0 
Median 746.41 667.77 30.45 26.4 43.94 6.27 
Range 242-1885 333-1678 6-100 6-100 0-348 0-93 
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 The median basic TK concentration was 30.45 U/l, but this fell to 
26.40 U/l after the 1st CC cycle (p=0.03). The decrease in TK concentration 
in relation to baseline values after completed treatment was statistically 
significant in each group: CR, PR and NR (p=0.001). The median TK value 
was 18.55 U/l in CR patients, 35 U/l in PR patients and 84.1 U/l in NR 
patients. While the median TK level increased in CLL non-responders, 
decreased in CR patients after the 1st cycle. 
 The median basic bFGF concentration was 43.94 pg/ml, but this fell 
to 6.27pg/ml (p=0.001) after the 1st CC cycle, which is lower than that 
observed in the control group (9.4pg/ml, p=0.001). The median basic 
concentration of bFGF in the group of patients with the following treatment 
response was observed: 140.29 pg/ml in CR patients, 76.6 pg/ml in PR 
patients, and 42.47 pg/ml in NR patients. The greatest decreased of 
concentration was calculated between CR and NR groups (p=0.0017).  
 The bFGF levels fell after the first cycle of treatment in all but one 
patient (CLL21), who died during the chemotherapy schedule after the 3rd 
CC cycle. In this case, very high levels of bFGF, TK and BFL1 protein and 
gene expression were observed before treatment (Table 3, 4).  
 Table 3a presents together three measured serum markers expression 
for particular single patient, which could give the proper view about patient 
markers expression reduction as a result of CC administration. This could 
prove a proper value of this potential marker in diagnostics for particular 
patients. If we observe both factors TK and bFGF over-expressed in one 
patient we can assume an active disease with high proliferation index and it 
could be a good marker for active proliferative disease status or disease 
conversion to active secondary cancer, what could happened sometimes even 
after aggressive chemotherapy. 
Table 4. Relationship between BFL1 gene and protein expression. 
Patient 
Gene Protein 
ΔΔCt RQ Mean MFI variance 
CLL 1 1.85 0.27  135.96 
CLL 2 0.20 1.64  21.18 
CLL 5 0 1.00  44.55 
CLL 6 3.01 0.10  208.16 
CLL 8 − 0.87 4.77  709.49 
CLL 9 − 0.55 1.46  104.65 
CLL 10 1.20 0.60  135.60 
CLL 11 − 1.38 2.60  210.14 
CLL 12 0.94 0.78  243.79 
CLL 13 3.63 0.05  418.33 
CLL 15 − 0.28 2.65  735.53 
CLL 16 1.24 0.42  91.05 
CLL 17 − 0.64 3.79  600.83 
CLL 18 − 0.21 2.47  179.86 
CLL 20 5.87 0.01  1327.4 
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CLL 21 − 0.74 4.19  624.11 
Upregulated gene (RQ ≥ 2.5) is in bold. 
 - Down and  - upregulation of expression. 
ΔΔCt  - comparative cycle threshold method 
MFI – mean fluorescence intensity; RQ – fold change 
 
BFL1  expression   
Protein expression 
 BFL1 expression was significantly higher in CLL patients than 
healthy volunteers (p=0.001). Its basic median expression was 746.41 MFI, 
which fell to 667.77 MFI after the 1st CC cycle (p=0.03), but it still did not 
reach the control group value (248.48 MFI). The median basic expression of 
BFL1 in the group of patients with CR, PR and NR was 660.77 MFI, 665.13 
and 927.75 MFI respectively. The decrease in BFL1 protein expression after 
the 1st cycle of treatment compared between groups of patients who 
responded to treatment (CR+PR) and NR was statistically significant 
(p=0.009) as well as the difference between CR and NR group (p=0.01) 
(Table 3, Fig. 2). 
Fig. 2.  The cytometric analysis of BFL-1 protein changes after CC treatment 
A. B. 
 
A. Before treatment; B. After 2 weeks of the infusion of CC first cycle 
 
Correlations between markers 
 The following statistically significant correlations between studied 
markers were found: a positive correlation between BFL1 and TK (r=0.52, 
p=0.01) median measured after 1st CC cycle.  
 
Gene expression studies 
qPCR array analysis 
 The purpose of this analysis was to identify genes with the greatest 
differential expression (DE) in the group of 7 CC patients (economic 
reasons) before and after 2 weeks of the first cycle treatment. The analysis 
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was based on the RQ measurement, which can be interpreted as the ratio of 
gene expression after treatment to gene expression before treatment 
(Franiak-Pietryga, et al., 2012b).  
 Most of the examined genes were down-regulated after treatment. 
The up-regulation was observed in 37 different genes at least in one patient 
due to treatment. The greatest up-regulation was detected in subsequent 
genes: BAK, BAX, BIRC1 (Table 5). Although some variations in the 
expression of particular genes between CLL patients were evident, the 
unsupervised hierarchical clustering, revealed two distinct expression 
patterns: the first one represented by patients cc2, cc5, cc8 and the second 
one by cc3, cc6, cc7 (Fig. 1). The cc2 patient could be regarded as an outlier 
because indicated down-regulation in expression in almost all genes. The 
first group contains the following genes in overexpression: HRK, BIRC1, 
BIRC8 as well as BNIP3 and BCL2L2.  
Table 5.  The greatest differences in expression of particular genes in CLL patients treated 
with CC. 
Gene MCL1 BCL2 BCL2A1 BCL2L1 BCL2L2 
Patient ddCt RQ ddCt RQ ddCt RQ ddCt RQ ddCt RQ 
cc2 3.21 0.08 3.79 0.05 3.72 0.05 -0.04 2.09 2.59 0.15 
cc3 0.02 1.95 0.40 1.34 -0.30 2.70 0.97 0.76 0.43 1.31 
cc4 0.44 1.29 0.91 0.80 -0.53 3.39 -0.28 2.66 0.67 1.02 
cc5 0.88 0.83 0.89 0.82 0.37 1.38 1.77 0.34 0.82 0.88 
cc6 -0.79 4.39 -0.38 2.94 -0.27 2.63 -1.23 6.87 0.28 1.51 
cc7 0.03 1.94 0.15 1.72 -1.26 7.05 -0.93 5.08 0.68 1.02 
cc8 0.04 1.91 1.05 0.70 -0.29 2.68 0.73 0.96 1.69 0.37 
 
BFL1 mRNA RT-PCR validation 
 BFL1 mRNA expression was assessed in 16 patients before and after 
treatment. It was upregulated 2.5-fold in 6/16 cases. In 13/16 cases, the 
expression of BFL1 mRNA was correlated with the protein. The down-
regulation in mRNA BFL1 and lower protein expression was identified in 
10/16 patients after the 1st CC cycle (Table 4). 
 
Discussion 
 CLL is a lymphoproliferative disorder in which BCL2 is expressed 
from an unrearanged locus (Schena, et al., 1992). Leukemic B-cells circulate 
in the peripheral blood but also exist in lymph nodes, where they 
demonstrate down-regulation of BCL2 and other pro-survival proteins, 
BCL2L1 and BFL1, are induced. Similar changes occur during normal B-cell 
maturation (Willimott, Baou, Naresh, & Wagner, 2007), (Vogler, et al., 
2009). Although peripheral blood B-cells express BCL2, it is repressed 
following the encounter with antigens and T-cells on entry to the germinal 
center, and BCL2L1 and BFL1 are induced (Vogler, et al., 2009). BCL2 
inhibits cell cycle entry and its overexpression reduces proliferation (Korz, et 
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al., 2002), (Huang, O’Reilly, Strasser, & Cory, 1997), (O’Reilly, Harris, 
Tarlinton, Corcoran, & Strasser, 1997).  
 Knowledge of the regulation of BCL2 is controversial. While BCL2 
mRNA has been detected in situations in which there is no BCL2 protein, 
suggesting that BCL2 is post-transcriptionally regulated, microarray and 
real-time PCR gene expression studies have confirmed the presence of an 
association between mRNA and protein levels (Chleq-Deschamps, et al., 
1993), (Kondo, et al., 1992), (Husson et al., 2002), (Klein, et al., 2003), 
(Shen, Iqbal, Huang, Zhou, & Chan, 2004). Our findings indicate that in 
most cases, BFL1 protein expression parallels mRNA level after treatment.  
 Although this study included too few patients to draw final 
conclusions, BFL1, TK and bFGF levels were found to be higher in NR 
patients than in CR and PR patients. Olsson et al. have also shown high 
BFL1 mRNA expression in leukemic cells from chemotherapy refractory B-
CLL patients (Olsson, et al., 2007). Using microarrays, they report a pattern 
of high expression levels of BFL1, BCL2 and MCL1 mRNA in apoptosis-
resistant B-CLL cells (Morales, et al., 2005). Other studies have also 
confirmed significantly higher expression of BCL2 in the refractory patients 
(Olsson, et al., 2007). Although most patients with NR in the present study 
were found to have very high levels of BFL1 protein and mRNA, others 
were also found with low basic level of BFL1 (CLL22), which increased 
after treatment. Our microarray study revealed BFL1 overexpression in the 
cluster of patients with unmutated-IGHV and no response. The strongest 
difference between non-responding and responding patients was observed 
when at least one of the two genes (BFL1 and BCL2 considered together) 
was overexpressed, as characterized by the NR group. In contrary, low 
expression of both studied genes was typical for patients who responded to 
therapy. This is in agreement with Olsson et al. (2007). Our microarray data 
confirm the above-mentioned data. These findings indicate that the 
expression of both BFL1 and BCL2, as well as other members of BCL2 
family, for example MCL1, may be a good predictor for chemotherapy 
response (Olsson, et al., 2007), (Rogalińska, et al., 2013). However, there is 
some dose of uncertainty whether high mRNA BFL1 expression levels is 
predictive of chemotherapy outcome or if is it a result of resistance 
development.  
 Five of the eight NR (CLL4, 7, 13, 21, 22) patients in the present 
study demonstrated parallel elevation of BFL1 and TK. The protein BFL1 
expression acted similar to TK concentration in reference to treatment 
response. In 9 patients, expression decreased after 2 weeks of the 1st CC 
cycle, whereas higher expression was observed in 5 cases. This correlation 
may be characteristic of CLL patients with very poor prognosis.  
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 A number of serological parameters such as TK and β2-M have been 
shown to provide information on CLL outcome (Hallek, et al., 1999). It has 
been shown that TK levels correlate with the proliferative activity of CLL 
cells and elevated levels predict disease progression (Zenz, Fröhling, 
Mertens, Döhner, & Stilgenbauer, 2010). Some studies have also shown that 
the serum TK level could be an independent predictor of the duration of the 
progression-free interval in CLL (Stilgenbauer, et al., 2009), (Hallek, et al., 
1996) and could stratify patients to the smouldering and non-smouldering 
stages of CLL (Hallek, et al., 1999). It still remains unclear whether the TK 
level can be used to predict response and the length of survival in patients 
with CLL. Raimondo et al., (2001) measured the TK level in a cohort of 
patients with active or advanced CLL (treated with fludarabine), correlated 
the serum TK level with other presenting features, and assessed the TK level 
as a prognostic indicator of both response and survival. They confirm that 
serum TK level in CLL patients provides useful prognostic information 
regarding both response to therapy and length of survival and should be used 
in planning appropriate therapy. In particular, patients with a TK level of ≥ 
10 U/l had a poor prognosis and should be considered for aggressive 
treatment (Raimondo et al., 2001). The results of our study indicate that not 
only elevated TK levels before treatment but also an increase in TK serum 
level after the first chemotherapy cycle can be useful in predicting response 
to therapy and survival. TK median level in CLL non-responders increased, 
whereas in CR patients it decreased after 1st cycle of chemotherapy. 
 In this study, markedly higher bFGF levels were found in CLL 
patients than in control group. Moreover, a negative correlation was 
observed between bFGF and CD38 before treatment (r= -0.63, p<0.004). It 
had been already reported that bFGF induce apoptotic resistance through up-
regulation of BCL2 (König, et al., 1997), (Bairey, Zimra, Shaklai, & 
Rabizadeh, 2001). Moreover, the elevation of bFGF correlates with stage of 
CLL and it associated with resistance to fludarabine (Menzel, et al., 1996). In 
a previous study, Gora-Tybor at al. (2002) found that the purine analog 
cladribine used in monotherapy downregulated the bFGF levels as well as 
other angiogenic factors in patients with CLL. Our results confirm that 
cladribine decreases bFGF serum concentration, not only in monotherapy but 
also when combined with cyclophosphamide.  
 
Conclusion 
 This analysis demonstrates that the CC regimen induces a relatively 
high response rate in patients with previously untreated CLL patients. High 
basic TK concentrations and overexpression of BFL1/BFL1 are associated 
with inferior response to therapy. BFL1 contributes to chemoresistance and 
may be a co-existing prognostic factor in CLL in the future. Further studies 
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on a bigger group of patients are needed to elucidate the role of BFL1 as a 
predictive marker in CLL.  
 Although many discoveries have been made in CLL biology, 
interaction with the microenvironment is of pivotal importance in the search 
for new drug targets. The biological characterisation of CLL has led to great 
progress being made in outcome prediction, and novel treatment strategies 
are being found based on a growing number of agents, opening entirely new 
therapeutic approaches. 
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